4SC AG |
Market Closed -
Other stock markets
|
Pre-market 11:02:01 am | |||
| 6.54 EUR | -3.82% |
|
6.88 | +5.20% |
| Sales 2022 | 436K 467K 39.06M | Sales 2023 | 304K 326K 27.23M | Capitalization | 89.51M 95.95M 8.02B |
|---|---|---|---|---|---|
| Net income 2022 | -14M -15.01M -1.25B | Net income 2023 | -8M -8.58M -717M | EV / Sales 2022 | -4.31 x |
| Net cash position 2022 | 14.82M 15.89M 1.33B | Net cash position 2023 | 5.22M 5.59M 468M | EV / Sales 2023 | 277 x |
| P/E ratio 2022 |
-0.9
x | P/E ratio 2023 |
-10.9
x | Employees | 13 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 26.68% |
More Fundamentals
* Assessed data
| 1 day | +5.20% | ||
| 1 week | -14.84% | ||
| Current month | -20.24% | ||
| 1 month | -21.96% | ||
| 3 months | -28.13% | ||
| 6 months | -23.06% | ||
| Current year | -26.10% |
1 week
6.54
7.50
1 month
6.548.38
Current year
6.5411.20
1 year
6.0011.50
3 years
1.1018.10
5 years
1.1018.10
10 years
1.1043.25
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/24/20 | 6.54 | -3.82% | 162 |
| 19/24/19 | 6.8 | -9.33% | 3,200 |
| 18/24/18 | 7.5 | 0.00% | 570 |
| 17/24/17 | 7.5 | 0.00% | 0 |
| 14/24/14 | 7.5 | -2.34% | 200 |
Delayed Quote Deutsche Boerse AG, June 21, 2024 at 12:00 am IST
More quotes
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Companyâs product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Calendar
08/08/2024
- Q2 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -26.10% | 71.53M | |
| +15.85% | 122B | |
| +18.91% | 113B | |
| +4.43% | 22.84B | |
| -18.63% | 20.72B | |
| -13.76% | 16.39B | |
| -16.61% | 16.51B | |
| -43.53% | 15.83B | |
| +1.75% | 13.49B | |
| +28.07% | 11.67B |
- Stock Market
- Equities
- VSC Stock
